Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mendelics | RCV000709022 | SCV000838223 | likely benign | Hereditary cancer | 2024-01-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000947013 | SCV001093177 | likely benign | EGFR-related lung cancer | 2025-01-19 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002258796 | SCV002537697 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-11-15 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV002258796 | SCV005579566 | benign | Hereditary cancer-predisposing syndrome | 2024-08-23 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
ITMI | RCV000120699 | SCV000084860 | not provided | not specified | 2013-09-19 | no assertion provided | reference population | |
Genetic Services Laboratory, |
RCV000120699 | SCV003839464 | uncertain significance | not specified | 2022-06-20 | no assertion criteria provided | clinical testing | DNA sequence analysis of the EGFR gene demonstrated a sequence change, c.3467A>C, in exon 28 that results in an amino acid change, p.His1156Pro. This sequence change does not appear to have been previously described in individuals with EGFR-related disorders. This sequence change has been described in the gnomAD database with a frequency of 0.18% in the African subpopulation (dbSNP rs149174093). The p.His1156Pro change affects a poorly conserved amino acid residue located in a domain of the EGFR protein that is known to be functional. The p.His1156Pro substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.His1156Pro change remains unknown at this time. |